<html><head></head><body><h1>Antacids</h1><p class="drug-subtitle"><b>Class:</b> Antacids and Adsorbents<br/>
- Antiulcer Agents<br/>
<b>ATC Class:</b> A02A<br/>
<b>VA Class:</b> GA209<br/>
<b>CAS Number:</b> 53547-27-6<br/>
<b>Brands:</b> Alamag, Alamag Plus, Alka-Mints, Alka-Seltzer Gold Effervescent Antacid, Almacone, Almacone II Hi-Potency, ALternaGEL, Alu-Cap, Alu-Tab, Amphojel, Basaljel, Chooz, Citrocarbonate Granules, Di-Gel, Gaviscon, Gaviscon Extra Strength, Genaton, Kudrox, Lowsium, Lowsium Plus, Maalox, Maalox Advanced Regular Strength, Maalox Advanced Maximum Strength, Maalox Antacid/Anti-Gas Maximum Strength, Maalox Max Quick Dissolve Chewables Antacid/Antigas Maximum Strength, Maalox Quick Dissolve Chewables, Maalox Quick Dissolve Chewables Maximum Strength, Maalox TC, Mag-Al, Mag-Al Plus, Mag-Al XS, Mag-Ox, Marblen, Milk of Magnesia, Mygel, Mygel II, Mylanta, Mylanta Children’s Upset Stomach Relief, Mylanta Fast-Acting, Mylanta Fast-Acting Double Strength, Mylanta Fast-Acting Maximum Strength, Mylanta Supreme Fast Acting, Pepcid Complete, Phillips’ Milk of Magnesia, Riopan Plus, Riopan Plus Double Strength, Rolaids Antacid, Rulox, Tempo, Titralac Extra Strength, Titralac Plus, Titralac Regular, Tums Antacid/Calcium Supplement, Tums E-X Antacid/Calcium Supplement, Tums Ultra Antacid/Calcium Supplement, Uro-Mag</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Inorganic salts that partially neutralize gastric hydrochloric acid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Antacids</h2><h3>Peptic Ulcers</h3><p>Adjunct to other drugs (e.g., anti-infectives, histamine H<sub>2</sub>-receptor antagonists, proton-pump inhibitors) for the relief of peptic ulcer pain and to promote the healing of peptic ulcers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Because of the inconvenience of the regimens needed to promote ulcer healing, high recurrence rate, ineffectiveness in eradicating <i>Helicobacter pylori</i>, palatability issues, and adverse effects, antacids rarely are used alone any longer for the treatment of peptic ulcer disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Instead, antacids currently are used principally as an adjunct to other antiulcer regimens for as-needed (prn) relief of peptic ulcer pain.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Acid Indigestion</h3><p><i>Self-medication</i> for the relief of acid indigestion (dyspepsia), heartburn, and sour stomach and/or bloating (commonly referred as gas).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Gastroesophageal Reflux Disease (GERD)</h3><p><i>Self-medication</i> for the relief of mild forms of GERD (e.g., symptoms induced by a heartburn-inducing meal).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antacids generally provide more rapid but less prolonged relief of GERD symptoms compared with histamine H<sub>2</sub>-receptor antagonists, and combined therapy generally is more effective than either class of drugs alone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult a clinician if symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Other agents (e.g., histamine H<sub>2</sub>-receptor antagonists, proton-pump inhibitors) preferred by American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) for management of more severe forms of GERD.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Have been used for <i>self-medication</i> for the relief of breakthrough symptoms in patients receiving proton-pump inhibitors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Hyperphosphatemia</h3><p>Aluminum-containing antacids (except aluminum phosphate): Management of hyperphosphatemia or prevention of recurrent phosphatic renal calculi (in conjunction with a low phosphate diet).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Aluminum carbonate generally preferred to aluminum hydroxide for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Calcium Replacement</h3><p>Calcium carbonate is used for calcium supplementation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Stress Ulceration and GI Bleeding</h3><p>Has been used for prevention of stress ulceration† and GI bleeding†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Gastric Acid Aspiration</h3><p>Has been used for prevention of gastric acid aspiration† in patients undergoing cesarean section or emergency surgery;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; generally has been replaced by histamine H<sub>2</sub>-receptor antagonist or citrate solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Antacids Dosage and Administration</h2><h3>Administration</h3><p>Administer orally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Oral suspensions more rapidly and effectively solubilized than powders or tablets; reserve oral tablets for chronic use in patients who refuse oral suspensions because of inconvenience or unpalatable taste.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Rapidly disintegrating tablets may be a suitable alternative in some patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chew tablets, including rapidly dissolving tablets, thoroughly before swallowing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as various inorganic salts (e.g., aluminum carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium bicarbonate); dosage is expressed in terms of mEq of acid neutralizing capacity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dose and frequency of administration depend on the acid secretory rate of the stomach, gastric emptying time, and the disorder being treated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For peptic ulcer disease, dosages of antacids are empirical and various antacid dosages have been used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For supplemental ulcer pain relief, 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Other therapies currently are preferred for treatment of active peptic ulcers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;200&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;238&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Peptic Ulcers under Uses.)</p><p>If antacids are used for the treatment of peptic ulcers, usual high-dose regimens for ulcer healing employ 80–160 mEq acid neutralizing capacity, given 1 and 3 hours after meals and at bedtime.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Additional doses of antacids may be administered to relieve ulcer pain that occurs between regularly scheduled doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with duodenal ulcers, antacids usually are given for 4–6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If symptoms of duodenal ulcer recur, antacids can be administered 1 and 3 hours after meals and at bedtime for 1 week and, if pain is relieved, less frequently for an additional 1–2 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with gastric ulcers, antacids are administered until healing is complete.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For GERD, dosages of antacids are empirical and various antacid dosages have been used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For relief of heartburn, one recommended regimen employs 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis intially.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If necessary, dosage can be titrated to a regularly scheduled basis such as 40–80 mEq acid neutralizing capacity given after meals and at bedtime.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In conjunction with dietary phosphate restriction in the management of hyperphosphatemia, 30–40 mL of aluminum hydroxide or aluminum carbonate suspension is administered 3 or 4 times daily.</p><p>For calcium replacement dosage with calcium carbonate, see Dosage in Calcium Salts 40:12.</p><p>In the management of stress ulceration† and GI bleeding†, antacids are usually administered every hour, and the antacid dosage should be titrated to maintain the nasogastric aspirate above pH 3.5.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For severe symptoms, antacid suspensions may be diluted with water or milk and given by continuous intragastric infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To reduce the risk of anesthesia-induced gastric acid aspiration, an antacid suspension has been given 30 minutes before anesthesia.</p><h3>Prescribing Limits</h3><p>Do not exceed 500–600 mEq acid neutralizing capacity daily or regularly scheduled (versus as-needed; prn) therapy for longer than 2 weeks continuously.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;f&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum daily dosage of sodium or bicarbonate is 200 mEq in patients &lt;60 years of age and 100 mEq in patients &gt;60 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated for prolonged therapy because it may cause metabolic alkalosis or sodium overload.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Antacids</h2><h3>Contraindications</h3><ul>
<li>
<p>Sodium bicarbonate is contraindicated and use of other sodium-containing antacids should be restricted in patients on low-sodium diets and in those with CHF, renal failure, edema, or cirrhosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Sodium bicarbonate is contraindicated and use of other sodium-containing antacids should be restricted in patients on low-sodium diets and in those with CHF, renal failure, edema, or cirrhosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Some antacids may contain aspartame (e.g., NutraSweet<sup></sup>), which is metabolized in the GI tract to phenylalanine following oral administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some antacid formulations contain the dye tartrazine (FD&amp;C yellow No. 5), which may cause allergic-type reactions (bronchial asthma in susceptible individuals) in certain susceptible individuals (e.g., patients who are sensitive to aspirin).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of hypophosphatemia with prolonged administration or large doses, particularly in patients with inadequate dietary intake of phosphorus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum phosphate concentrations at monthly or bimonthly intervals in patients on maintenance hemodialysis who are receiving chronic aluminum antacid therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause gastric hypersecretion and acid rebound.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause the milk-alkali syndrome (characterized by hypercalcemia, metabolic alkalosis and, rarely, renal insufficiency).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum calcium concentrations weekly and whenever manifestations of hypercalcemia occur in patients receiving large doses of calcium carbonate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Commonly cause a laxative effect, and frequent administration of these antacids alone often cannot be tolerated; repeated doses cause diarrhea which may cause fluid and electrolyte imbalances.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause metabolic alkalosis when given in large doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serious medication errors have been reported to FDA in which consumers used Maalox<sup></sup> Total Relief (bismuth subsalicylate) when they intended to use traditional Maalox<sup></sup> liquid antacid products containing aluminum hydroxide, magnesium hydroxide, and simethicone (e.g., Maalox<sup></sup> Advanced Regular Strength, Maalox<sup></sup> Advanced Maximum Strength).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;266&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;268&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Because of the potential for serious adverse effects associated with accidental use of bismuth subsalicylate (which is chemically related to aspirin), the manufacturer of Maalox<sup></sup> Total Relief initially agreed to change the trade name of the product to one that did not include “Maalox”; however, the manufacturer instead discontinued the bismuth subsalicylate preparation in the summer of 2010.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;269&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Aluminum Antacids: Long-term administration in patients with renal failure or chronic renal failure may result in hyperaluminemia since small amounts of aluminum are absorbed from the GI tract and excretion of aluminum is decreased in patients with renal failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Aluminum accumulation in the CNS may be the cause of dialysis encephalopathy, while aluminum accumulation in the bones may result in or worsen dialysis osteomalacia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Calcium Carbonate: Patients with renal impairment or dehydration and electrolyte imbalance are predisposed to developing the milk-alkali syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hypercalcemia risk in chronic hemodialysis patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Magnesium Antacids: In patients with severe renal impairment, hypermagnesemia characterized by hypotension, nausea, vomiting, ECG changes, respiratory or mental depression, and coma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not administer in patients with renal failure, and antacids containing more than 50 mEq of magnesium in the recommended daily dosage should be used cautiously and only under the supervision of a clinician who should monitor electrolytes in patients with renal disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sodium Bicarbonate: May cause metabolic alkalosis in patients with renal insufficiency.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>With prolonged administration, constipation (e.g., aluminum salts, calcium carbonate), diarrhea (e.g., magnesium salts), gastric distension/flatulence (e.g., sodium bicarbonate), and gastric hypersecretion/acid rebound (e.g., calcium carbonate).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Antacids</h2><p>All antacids potentially may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs by changing GI transit time or by binding or chelating the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In vitro studies indicate that magnesium hydroxide or trisilicate has the greatest potential for drug binding and aluminum hydroxide and calcium carbonate are intermediate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs and Food</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Aspirin</p><p>Pharmacokinetic (increased absorption of buffered or enteric-coated aspirin or decreased blood salicylate concentrations) interactions&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Chlordiazepoxide</p><p>Possible decreased chlordiazepoxide absorption with aluminum hydroxide and magnesium preparations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diazepam</p><p>Possible increased diazepam absorption with aluminum hydroxide&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Digoxin</p><p>Possible decreased digoxin absorption&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Space doses of the drugs as far apart as possible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Indomethacin</p><p>Possible decreased indomethacin absorption&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Space doses of the drugs as far apart as possible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Iron salts</p><p>Possible decreased absorption of iron salts&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Space doses of the drugs as far apart as possible&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Isoniazid</p><p>Possible decreased isoniazid absorption with aluminum hydroxide&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer isoniazid at least 1 hour before aluminum-containing antacids&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Milk or other calcium-containing foods</p><p>Possible milk-alkali syndrome with chronic administration of bicarbonate and milk or calcium&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Naproxen</p><p>Possible increased naproxen absorption with sodium bicarbonate&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible decreased naproxen absorption with magnesium oxide or aluminum hydroxide&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pseudoephedrine</p><p>Possible increased pseudoephedrine absorption with aluminum hydroxide&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tetracyclines</p><p>Possible decreased tetracycline absorption&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Allow 1–2 hours to elapse between doses of antacids and tetracyclines&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Mechanism of action in the treatment of peptic ulcers is based on ability of antacids to react with hydrochloric acid and thus increase gastric pH.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>With usual doses, antacids generally do not increase and maintain gastric pH above 4–5.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Antacids, in decreasing order of their ability to neutralize a given amount of acid, are calcium carbonate, sodium bicarbonate, magnesium salts, and aluminum salts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Aluminum-containing antacids (except aluminum phosphate) combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminum phosphate which is excreted in the feces.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If phosphate intake is limited and renal function is normal, aluminum antacids (except aluminum phosphate) decrease phosphate absorption and hypophosphatemia and hypophosphaturia occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Magnesium-containing antacids have a laxative action.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Mechanism of action in the treatment of peptic ulcers is based on ability of antacids to react with hydrochloric acid and thus increase gastric pH.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With usual doses, antacids generally do not increase and maintain gastric pH above 4–5.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antacids, in decreasing order of their ability to neutralize a given amount of acid, are calcium carbonate, sodium bicarbonate, magnesium salts, and aluminum salts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Aluminum-containing antacids (except aluminum phosphate) combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminum phosphate which is excreted in the feces.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If phosphate intake is limited and renal function is normal, aluminum antacids (except aluminum phosphate) decrease phosphate absorption and hypophosphatemia and hypophosphaturia occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Magnesium-containing antacids have a laxative action.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Advise patients to consult a clinician if ulcer pain worsens or is not relieved after the first week of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of consulting a clinician if GERD symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Advise patients to consult a clinician if ulcer pain worsens or is not relieved after the first week of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of consulting a clinician if GERD symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;265&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Capsules</p><p>equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg</p><p>Basaljel<sup></sup></p><p>Wyeth</p><p>Tablets</p><p>equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg</p><p>Basaljel<sup></sup> (scored)</p><p>Wyeth</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Capsules</p><p>475 mg</p><p>Alu-Cap<sup></sup></p><p>3M</p><p>Suspension</p><p>320 mg/5 mL*</p><p>Aluminum Hydroxide Suspension</p><p>Amphojel<sup></sup></p><p>Wyeth</p><p>600 mg/5 mL</p><p>ALternaGEL<sup></sup></p><p>J&amp;J-Merck</p><p>Tablets</p><p>300 mg</p><p>Amphojel<sup></sup></p><p>Wyeth</p><p>Tablets, film-coated</p><p>600 mg</p><p>Alu-Tab<sup></sup></p><p>3M</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>Oral</p><p>Pieces, chewing gum</p><p>500 mg</p><p>Chooz<sup></sup></p><p>Insight</p><p>Suspension</p><p>400 mg/5 mL</p><p>Mylanta<sup></sup> Children’s Upset Stomach Relief</p><p>J&amp;J-Merck</p><p>1.25 g/5 mL*</p><p>Calcium Carbonate Suspension</p><p>Tablets</p><p>1.25 g*</p><p>Calcium Carbonate Tablets (scored)</p><p>Tablets, chewable</p><p>400 mg</p><p>Mylanta<sup></sup> Children’s Upset Stomach Relief</p><p>J&amp;J-Merck</p><p>420 mg</p><p>Titralac<sup></sup> Regular</p><p>3M</p><p>500 mg</p><p>Tums<sup></sup> Antacid/Calcium Supplement</p><p>GlaxoSmithKline</p><p>650 mg*</p><p>Calcium Carbonate Chewable Tablets</p><p>750 mg</p><p>Titralac<sup></sup> Extra Strength</p><p>3M</p><p>Tums<sup></sup> E-X Antacid/Calcium Supplement</p><p>GlaxoSmithKline</p><p>850 mg</p><p>Alka-Mints<sup></sup></p><p>Bayer</p><p>1 g</p><p>Tums<sup></sup> Ultra Antacid/Calcium Supplement</p><p>GlaxoSmithKline</p><p>Tablets, chewable, rapidly disintegrating</p><p>600 mg</p><p>Maalox<sup></sup> Quick Dissolve<sup></sup> Chewables</p><p>Novartis</p><p>1 g</p><p>Maalox<sup></sup> Quick Dissolve<sup></sup> Chewables Maximum Strength</p><p>Novartis</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>540 mg/5 mL</p><p>Lowsium<sup></sup></p><p>Rugby</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>540 mg/5 mL with Simethicone 40 mg/5 mL</p><p>Lowsium<sup></sup> Plus</p><p>Rugby</p><p>Riopan Plus<sup></sup></p><p>Wyeth</p><p>1080 mg/5 mL with Simethicone 40 mg/5mL</p><p>Riopan Plus<sup></sup> Double Strength</p><p>Wyeth</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>Oral</p><p>Suspension</p><p>400 mg/5 mL*</p><p>Milk of Magnesia</p><p>Phillips’<sup></sup> Milk of Magnesia</p><p>Bayer</p><p>800 mg/5 mL</p><p>Phillips’<sup></sup> Milk of Magnesia Concentrate</p><p>Bayer</p><p>1.2 g/5 mL*</p><p>Milk of Magnesia Concentrate</p><p>Roxane</p><p>Tablets</p><p>300 mg*</p><p>Phillips’<sup></sup> Milk of Magnesia</p><p>Bayer</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>Oral</p><p>Capsules</p><p>140 mg</p><p>Uro-Mag<sup></sup></p><p>Blaine</p><p>Tablets</p><p>400 mg*</p><p>Magnesium Oxide Tablets</p><p>Mag-Ox<sup></sup> 400</p><p>Blaine</p><p>420 mg*</p><p>Magnesium Oxide Tablets</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Bulk</p><p>Powder*</p><p>Oral</p><p>For solution</p><p>0.78 g/3.9 g</p><p>Citrocarbonate<sup></sup> Granules</p><p>Lee</p><p>Tablets</p><p>325 mg*</p><p>Sodium Bicarbonate Tablets</p><p>650 mg*</p><p>Sodium Bicarbonate Tablets</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Aluminum Hydroxide 31.7 mg/5 mL and Magnesium Carbonate 119.3 mg/5 mL</p><p>Gaviscon<sup></sup> Liquid</p><p>GlaxoSmithKline</p><p>Genaton<sup></sup> Liquid</p><p>Teva</p><p>Aluminum Hydroxide 254 mg/5 mL and Magnesium Carbonate 237.5 mg/5 mL</p><p>Gaviscon<sup></sup> Extra Strength</p><p>GlaxoSmithKline</p><p>Tablets, chewable</p><p>Aluminum Hydroxide 160 mg and Magnesium Carbonate 105 mg</p><p>Gaviscon<sup></sup> Extra Strength</p><p>GlaxoSmithKline</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Aluminum Hydroxide 200 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL</p><p>Mag-Al<sup></sup></p><p>Pharmaceutical Associates</p><p>Aluminum Hydroxide 225 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL</p><p>Alamag<sup></sup></p><p>Teva, URL</p><p>Maalox<sup></sup></p><p>Novartis</p><p>Rulox<sup></sup></p><p>Rugby</p><p>Aluminum Hydroxide 600 mg/5 mL and Magnesium Hydroxide 300 mg/5 mL</p><p>Maalox<sup></sup> TC</p><p>Novartis</p><p>Tablets, chewable</p><p>Aluminum Hydroxide 200 mg and Magnesium Hydroxide 200 mg</p><p>Rulox<sup></sup> #1</p><p>Rugby</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Aluminum Hydroxide 200 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 20 mg/5 mL</p><p>Almacone<sup></sup></p><p>Rugby</p><p>Di-Gel<sup></sup></p><p>Schering-Plough</p><p>Maalox Advanced Regular Strength<sup></sup></p><p>Novartis</p><p>Mag-Al<sup></sup> Plus</p><p>Pharmaceutical Associates</p><p>Mygel<sup></sup></p><p>Sandoz</p><p>Mylanta<sup></sup> Fast-Acting</p><p>J&amp;J-Merck</p><p>Aluminum Hydroxide 225 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 25 mg/5 mL</p><p>Alamag<sup></sup> Plus</p><p>Teva</p><p>Aluminum Hydroxide 400 mg/5 mL, Magnesium Hydroxide 400 mg/5 mL, and Simethicone 40 mg/5 mL</p><p>Almacone<sup></sup> II Hi-Potency</p><p>Rugby</p><p>Antacid Double Strength<sup></sup></p><p>Teva</p><p>Maalox Advanced Maximum Strength<sup></sup></p><p>Novartis</p><p>Mag-Al<sup></sup> XS</p><p>Pharmaceutical Associates</p><p>Mygel<sup></sup> II</p><p>Sandoz</p><p>Mylanta<sup></sup> Fast-Acting Double Strength</p><p>J&amp;J-Merck</p><p>Aluminum Hydroxide 500 mg/5 mL, Magnesium Hydroxide 450 mg/5 mL, and Simethicone 40 mg/5 mL</p><p>Kudrox<sup></sup></p><p>Schwarz</p><p>Maalox<sup></sup> Antacid/Anti-Gas Maximum Strength</p><p>Novartis</p><p>Tablets, chewable</p><p>Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg</p><p>Almacone<sup></sup></p><p>Rugby</p><p>Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 25 mg</p><p>Tempo<sup></sup></p><p>Blairex</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets, chewable</p><p>Aluminum Hydroxide 80 mg and Magnesium Trisilicate 20 mg</p><p>Gaviscon<sup></sup></p><p>GlaxoSmithKline</p><p>Genaton<sup></sup></p><p>Teva</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Calcium Carbonate 520 mg/5 mL and Magnesium Carbonate 400 mg/5 mL</p><p>Marblen<sup></sup></p><p>Fleming</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Calcium Carbonate 400 mg/5 mL and Magnesium Hydroxide 135 mg/5 mL</p><p>Mylanta<sup></sup> Supreme Fast Acting</p><p>J&amp;J-Merck</p><p>Tablets</p><p>Calcium Carbonate 550 mg and Magnesium Hydroxide 125 mg</p><p>Mylanta<sup></sup> Gelcaps<sup></sup></p><p>J&amp;J-Merck</p><p>Tablets, chewable</p><p>Calcium Carbonate 350 mg and Magnesium Hydroxide 150 mg</p><p>Mylanta<sup></sup> Fast-Acting</p><p>J&amp;J-Merck</p><p>Calcium Carbonate 500 mg and Magnesium Hydroxide 110 mg</p><p>Rolaids<sup></sup> Antacid</p><p>Pfizer</p><p>Calcium Carbonate 700 mg and Magnesium Hydroxide 300 mg</p><p>Mylanta<sup></sup> Fast-Acting Maximum Strength</p><p>J&amp;J-Merck</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets</p><p>Calcium Carbonate 280 mg, Magnesium Hydroxide 128 mg, and Simethicone 20 mg</p><p>Di-Gel<sup></sup></p><p>Schering-Plough</p><p>Tablets, chewable</p><p>Calicum Carbonate 800 mg, Magnesium Hydroxide 165 mg, and Famotidine 10 mg</p><p>Pepcid<sup></sup> Complete</p><p>J&amp;J-Merck</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets</p><p>420 mg with Simethicone 21 mg</p><p>Titralac<sup></sup> Plus</p><p>3M</p><p>Tablets, chewable, rapidly disintegrating</p><p>1 g with Simethicone 60 mg</p><p>Maalox<sup></sup> Max<sup></sup> Quick Dissolve Chewables Antacid/Antigas Maximum Strength</p><p>Novartis</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets, for solution</p><p>Potassium Bicarbonate 312 mg and Sodium Bicarbonate 958 mg</p><p>Alka-Seltzer<sup></sup> Gold Effervescent Antacid</p><p>Bayer</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions February 1, 2011. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>200. Ateshkadi A, Lam NP, Johnson CA. <i>Helicobacter pylori</i> and peptic ulcer disease. <i>Clin Pharm</i>. 1993; 12:34-48. http://www.ncbi.nlm.nih.gov/pubmed/8428432?dopt=AbstractPlus</p><p>201. Blaser MJ. <i>Helicobacter pylori</i>: its role in disease. <i>Clin Infect Dis</i>. 1992; 15:386-91. http://www.ncbi.nlm.nih.gov/pubmed/1520782?dopt=AbstractPlus</p><p>202. Marshall BJ. Treatment strategies for <i>Helicobacter pylori</i> infection. <i>Gastroenterol Clin North Am</i>. 1993; 22:183-98. http://www.ncbi.nlm.nih.gov/pubmed/8449566?dopt=AbstractPlus</p><p>203. Bayerdörffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of <i>Helicobacter pylori</i> with a combination of omeprazole and amoxycillin. <i>Scand J Gastroenterol Suppl</i>. 1993; 196:19-25. http://www.ncbi.nlm.nih.gov/pubmed/8341987?dopt=AbstractPlus</p><p>204. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on <i>H. pylori</i> and duodenal ulcer disease. <i>Scand J Gastroenterol Suppl</i>. 1993; 196:17-8.</p><p>205. Hunt RH. Hp and pH: implications for the eradication of <i>Helicobacter pylori</i>. <i>Scand J Gastroenterol Suppl</i>. 1993; 196:12-6. http://www.ncbi.nlm.nih.gov/pubmed/8341986?dopt=AbstractPlus</p><p>206. Malfertheiner P. Compliance, adverse events and antibiotic resistance in <i>Helicobacter pylori</i> treatment. <i>Scand J Gastroenterol Suppl</i>. 1993; 196:34-7. http://www.ncbi.nlm.nih.gov/pubmed/8341989?dopt=AbstractPlus</p><p>207. Bell GD, Powell U. Eradication of <i>Helicobacter pylori</i> and its effect in peptic ulcer disease. <i>Scand J Gastroenterol Suppl</i>. 1993; 196:7-11. http://www.ncbi.nlm.nih.gov/pubmed/8341990?dopt=AbstractPlus</p><p>208. Farrell MK. Dr. Apley meets <i>Helicobacter pylori</i>. <i>J Pediatr Gastroenterol Nutr</i>. 1993; 16:118-9. http://www.ncbi.nlm.nih.gov/pubmed/8450375?dopt=AbstractPlus</p><p>209. Nomura A, Stemmermann GN, Chyou PH et al. <i>Helicobacter pylori</i> infection and gastric carcinoma among Japanese Americans in Hawaii. <i>N Engl J Med</i>. 1991; 325:1132-6. http://www.ncbi.nlm.nih.gov/pubmed/1891021?dopt=AbstractPlus</p><p>210. Parsonnet J, Friedman GD, Vandersteen DP et al. <i>Helicobacter pylori</i> infection and the risk of gastric carcinoma. <i>N Engl J Med</i>. 1991; 325:1127-31. http://www.ncbi.nlm.nih.gov/pubmed/1891020?dopt=AbstractPlus</p><p>211. The EUROGAST Study Group. An international association between <i>Helicobacter pylori</i> infection and gastric cancer. <i>Lancet</i>. 1993; 341:1359-62. http://www.ncbi.nlm.nih.gov/pubmed/8098787?dopt=AbstractPlus</p><p>212. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and <i>Helicobacter pylori</i> infection. <i>J Natl Cancer Inst</i>. 1991; 83:1734-9. http://www.ncbi.nlm.nih.gov/pubmed/1770552?dopt=AbstractPlus</p><p>213. Forman D, Newell DG, Fullerton F et al. Association between infection with <i>Helicobacter pylori</i> and risk of gastric cancer: evidence from a prospective investigation. <i>BMJ</i>. 1991; 302:1302-5. http://www.ncbi.nlm.nih.gov/pubmed/2059685?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1670011&amp;blobtype=pdf</p><p>214. Forman D. <i>Helicobacter pylori</i> infection: a novel risk factor in the etiology of gastric cancer. <i>J Natl Cancer Inst</i>. 1991; 83:1702-3. http://www.ncbi.nlm.nih.gov/pubmed/1770545?dopt=AbstractPlus</p><p>215. Parsonnet J. <i>Helicobacter pylori</i> and gastric cancer. <i>Gastroenterol Clin North Am</i>. 1993; 22:89-104. http://www.ncbi.nlm.nih.gov/pubmed/8449573?dopt=AbstractPlus</p><p>216. Correa P. Is gastric carcinoma an infectious disease? <i>N Engl J Med</i>. 1991; 325:1170-1.</p><p>217. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? <i>Hum Pathol</i>. 1993; 24:569-70.</p><p>218. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of <i>Helicobacter pylori</i>. <i>Lancet</i>. 1990; 335:1233-5. http://www.ncbi.nlm.nih.gov/pubmed/1971318?dopt=AbstractPlus</p><p>219. Hunt RH. pH and Hp—gastric acid secretion and <i>Helicobacter pylori</i>: implications for ulcer healing and eradication of the organism. <i>Am J Gastroenterol</i>. 1993; 88:481-3. http://www.ncbi.nlm.nih.gov/pubmed/8470623?dopt=AbstractPlus</p><p>220. Reviewers’ comments (personal observations) on <i>Helicobacter pylori</i>. Clarithromycin 8:12.12.</p><p>221. Marshall BJ. <i>Helicobacter pylori</i>. <i>Am J Gastroenterol</i>. 1994; 89(Suppl):S116-28.</p><p>222. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole <i>versus</i> triple therapy for eradication of <i>Helicobacter pylori</i> in duodenal ulcer disease: a prospective, randomized, and controlled study. <i>Gut</i>. 1993; 34:1167-70. http://www.ncbi.nlm.nih.gov/pubmed/8406147?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1375447&amp;blobtype=pdf</p><p>223. Anon. Drugs for treatment of peptic ulcer. <i>Med Lett Drugs Ther</i>. 1994; 36:65-7. http://www.ncbi.nlm.nih.gov/pubmed/7912812?dopt=AbstractPlus</p><p>224. Freston JW. Emerging strategies for managing peptic ulcer disease. <i>Scand J Gastroenterol Suppl</i>. 1994; 201:49-54. http://www.ncbi.nlm.nih.gov/pubmed/8047824?dopt=AbstractPlus</p><p>225. Axon ATR. The role of acid inhibition in the treatment of <i>Helicobacter pylori</i> infection. <i>Scand J Gastroenterol Suppl</i>. 1994; 201:16-23. http://www.ncbi.nlm.nih.gov/pubmed/8047818?dopt=AbstractPlus</p><p>226. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates <i>Helicobacter pylori</i> in gastric ulcer disease. <i>Am J Gastroenterol</i>. 1994; 89:726-30. http://www.ncbi.nlm.nih.gov/pubmed/8172146?dopt=AbstractPlus</p><p>227. Labenz J, Borsch G. Evidence for the essential role of <i>Helicobacter pylori</i> in gastric ulcer disease. <i>Gut</i>. 1994; 35:19-22. http://www.ncbi.nlm.nih.gov/pubmed/8307443?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1374625&amp;blobtype=pdf</p><p>228. NIH Consensus Development Panel on <i>Helicobacter pylori</i> in Peptic Ulcer Disease. <i>Helicobacter pylori</i> in peptic ulcer disease. <i>JAMA</i>. 1994; 272:65-9. http://www.ncbi.nlm.nih.gov/pubmed/8007082?dopt=AbstractPlus</p><p>229. Fennerty MB. <i>Helicobacter pylori</i>. <i>Ann Intern Med</i>. 1994; 154:721-7.</p><p>230. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin <i>Helicobacter pylori</i> eradication therapy. <i>Am J Gastroenterol</i>. 1994; 89:39-42. http://www.ncbi.nlm.nih.gov/pubmed/8273795?dopt=AbstractPlus</p><p>231. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. <i>JAMA</i>. 1994; 271:808-9. http://www.ncbi.nlm.nih.gov/pubmed/8114221?dopt=AbstractPlus</p><p>232. Feldman M. The acid test. Making clinical sense of the consensus conference on <i>Helicobacter pylori</i>. <i>JAMA</i>. 1994; 272:70-1. http://www.ncbi.nlm.nih.gov/pubmed/8007084?dopt=AbstractPlus</p><p>233. Markham A, McTavish D. Clarithromycin and omeprazole: as <i>Helicobacter pylori</i> eradication therapy in patients with H. pylori-associated gastric disorders. <i>Drugs</i>. 1996; 51:161-78. http://www.ncbi.nlm.nih.gov/pubmed/8741237?dopt=AbstractPlus</p><p>234. Soll AH. Medical treatment of peptic ulcer disease. <i>JAMA</i>. 1996; 275:622-9. http://www.ncbi.nlm.nih.gov/pubmed/8594244?dopt=AbstractPlus</p><p>235. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by <i>Helicobacter pylori</i>. <i>Clin Infect Dis</i>. 1992; 15(Suppl 1):S268-73.</p><p>236. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating <i>Helicobacter pylori</i>. <i>Am J Gastroenterol</i>. 1992; 87:1716-27. http://www.ncbi.nlm.nih.gov/pubmed/1449132?dopt=AbstractPlus</p><p>237. Glassman MS. <i>Helicobacter pylori</i> infection in children. A clinical overview. <i>Clin Pediatr (Phila)</i>. 1992; 31:481-7. http://www.ncbi.nlm.nih.gov/pubmed/1643767?dopt=AbstractPlus</p><p>238. Peterson WL. <i>Helicobacter pylori</i> and peptic ulcer disease. <i>N Engl J Med</i>. 1991; 324:1043-8. http://www.ncbi.nlm.nih.gov/pubmed/2005942?dopt=AbstractPlus</p><p>239. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of <i>Helicobacter pylori</i> positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. <i>Gut</i>. 1993; 34:466-9. http://www.ncbi.nlm.nih.gov/pubmed/8491391?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1374304&amp;blobtype=pdf</p><p>240. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 1994; 89:1785-8. http://www.ncbi.nlm.nih.gov/pubmed/7942667?dopt=AbstractPlus</p><p>241. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of <i>Helicobacter pylori</i>-associated duodenal ulcer. <i>Am J Gastroenterol</i>. 1994; 89:1793-6. http://www.ncbi.nlm.nih.gov/pubmed/7942669?dopt=AbstractPlus</p><p>242. Walsh JH, Peterson WL. The treatment of <i>Helicobacter pylori</i> infection in the management of peptic ulcer disease. <i>N Engl J Med</i>. 1995; 333:984-91. http://www.ncbi.nlm.nih.gov/pubmed/7666920?dopt=AbstractPlus</p><p>243. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of <i>Helicobacter pylori</i> infection. <i>Drug Saf</i>. 1996; 15:30-52. http://www.ncbi.nlm.nih.gov/pubmed/8862962?dopt=AbstractPlus</p><p>244. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of <i>Helicobacter pylori</i> in peptic ulcer disease. <i>Drugs</i>. 1995; 6:984-90.</p><p>245. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of <i>Helicobacter pylori</i> infection: a review of the world literature. <i>Helicobacter</i>. 1996; 1:6-19. http://www.ncbi.nlm.nih.gov/pubmed/9398908?dopt=AbstractPlus</p><p>246. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of <i>Helicobacter pylori</i> using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. <i>Helicobacter</i>. 1996; 1:138-44. http://www.ncbi.nlm.nih.gov/pubmed/9398894?dopt=AbstractPlus</p><p>247. Anon. The choice of antibacterial drugs. <i>Med Lett Drugs Ther</i>. 1996; 38:25-34. http://www.ncbi.nlm.nih.gov/pubmed/8598824?dopt=AbstractPlus</p><p>248. Graham DY, Go MF. Evaluation of new antiinfective drugs for <i>Helicobacter pylori</i> infection: revisited and updated. <i>Clin Infect Dis</i>. 1993; 17:293-4. http://www.ncbi.nlm.nih.gov/pubmed/8399892?dopt=AbstractPlus</p><p>249. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for <i>Helicobacter pylori</i> infection: revisited and updated.) <i>Clin Infect Dis</i>. 1993; 17:294-5.</p><p>250. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of <i>H. pylori</i>. <i>Med J Aust</i>. 1990; 153:145-9. http://www.ncbi.nlm.nih.gov/pubmed/1974027?dopt=AbstractPlus</p><p>251. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of <i>Helicobacter pylori</i>. <i>Lancet</i>. 1991; 337:1614. http://www.ncbi.nlm.nih.gov/pubmed/1675746?dopt=AbstractPlus</p><p>252. Marshall BJ. <i>Campylobacter pylori</i>: its link to gastritis and peptic ulcer disease. <i>Clin Infect Dis</i>. 1990; 12(Suppl 1):S87-93.</p><p>253. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. <i>Ann Intern Med</i>. 1991; 115:266-9. http://www.ncbi.nlm.nih.gov/pubmed/1854110?dopt=AbstractPlus</p><p>254. Hentschel E, Brandstätter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of <i>Helicobacter pylori</i> and the recurrence of duodenal ulcer. <i>N Engl J Med</i>. 1993; 328:308-12. http://www.ncbi.nlm.nih.gov/pubmed/8419816?dopt=AbstractPlus</p><p>255. Borody T, Andrews P, Mancuso N et al. <i>Helicobacter pylori</i> reinfection 4 years post-eradication. <i>Lancet</i>. 1992; 339:1295. http://www.ncbi.nlm.nih.gov/pubmed/1349686?dopt=AbstractPlus</p><p>256. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. <i>Arch Intern Med</i>. 1992; 152:726-32. http://www.ncbi.nlm.nih.gov/pubmed/1558429?dopt=AbstractPlus</p><p>257. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. <i>JAMA</i>. 1996; 276:1135. http://www.ncbi.nlm.nih.gov/pubmed/8827957?dopt=AbstractPlus</p><p>258. Soll AH. Practice guidelines for treatment of peptic ulcer disease. <i>JAMA</i>. 1996; 276:1136-7.</p><p>259. Bell GD. Anti-<i>Helicobacter pylori</i> therapy: clearance, elimination, or eradication? <i>Lancet</i>. 1991; 337:310-1. Letter.</p><p>260. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. <i>Drugs</i>. 1997; 54:473-500. http://www.ncbi.nlm.nih.gov/pubmed/9279507?dopt=AbstractPlus</p><p>261. TAP Pharmaceuticals, Inc. Prevacid<sup></sup> (lansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 1997 Aug.</p><p>262. Garnett RG. Lansoprazole: a proton pump inhibitor. <i>Ann Pharmacother</i>. 1996; 30:1425. http://www.ncbi.nlm.nih.gov/pubmed/8968456?dopt=AbstractPlus</p><p>263. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. <i>Pharmacotherapy</i>. 1997; 17:308-26. http://www.ncbi.nlm.nih.gov/pubmed/9085323?dopt=AbstractPlus</p><p>264. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. <i>Scand J Gastroenterol</i>. 1995; 11:1053-7.</p><p>265. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 1999; 94:1434-42. http://www.ncbi.nlm.nih.gov/pubmed/10364004?dopt=AbstractPlus</p><p>266. Food and Drug Administration. Maalox<sup></sup> total relief and Maalox<sup></sup> liquid products: medication use errors. Rockville, MD; 2010 Feb 17. From the FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200672.htm</p><p>267. Food and Drug Administration. Product confusion with Maalox<sup></sup> total relief and Maalox<sup></sup> liquid products. Rockville, MD; 2010 Feb 17. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm201098.htm</p><p>268. Food and Drug Administration warns about serious side effects from Maalox<sup></sup> product mix-ups. Rockville, MD; 2010 Feb 17. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200795.htm</p><p>269. Novartis Consumer Health, East Hanover: Personal communication.</p><p>a. Food and Drug Administration. Antacid products for over-the-counter (OTC) human use. [21 FR Part 331] Fed Regist. 1990; 55:19859.</p><p>b. AHFS drug information 2004. McEvoy GK, ed. Antacids. Bethesda, MD: American Society of Health-System Pharmacists; 2004:2756-61.</p><p>c. USP DI: drug information for the health care provider. Johnson KW, ed. 24th ed. Englewood, CO: Micromedex, Inc; 2004:202-21. Antacids (oral-local).</p><p>d. American Pharmaceutical Association. Handbook of nonprescriptin drugs. 14th ed. Washington, DC: American Pharmaceutical Association; 2004:317-48.</p><p>e. American Gastroenterological Association Consensus Development Panel. Improving the management of GERD: evidence-based therapeutic strategies. Bethesda, MD: AGA Press; 2002:1-24.</p><p>f. American Pharmaceutical Association. Handbook of nonprescriptin drugs. 13th ed. Washington, DC: American Pharmaceutical Association; 2004:267-303.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>